Healthcare (Prescription Drugs)

HB 1420 requires criminal history background checks for applicants and renewing licensees in specific healthcare professions, including nursing, dentistry, pharmacy, and others listed in the bill. Starting July 1, 2027, new applicants must submit fingerprints and pay fees to the state’s Central Repository for a criminal records check under new Section 1A-302.1. Existing licensees renewing after January 1, 2028, must also provide proof of a criminal check. The bill establishes standardized procedures for conducting these checks while ensuring confidentiality and allowing applicants to contest results.

HB 838 repeals a requirement that prescribers submit prescriber-pharmacist agreements to their regulating health board. Instead, it allows pharmacists (with specific qualifications, registrations, and training) to directly enter agreements authorizing them to treat opioid use disorder using controlled substances. A key provision requires pharmacists to check the Prescription Drug Monitoring Program (PDMP) for relevant patient data before starting or changing such therapy. This bill directly affects pharmacists, prescribers, and patients with opioid use disorder by expanding pharmacists' role in medication management under defined safeguards.

HB 1167 requires Maryland's Department of Health to replace its outdated Medicaid computer system with a modern, flexible system by 2028. The new system must maintain all current Medicaid functions - including processing medical/dental/pharmacy claims, provider enrollment, and beneficiary inquiries - while meeting federal security and performance standards. The bill mandates integration with existing Medicaid systems by January 2027 and full replacement of the old system by January 2028, subject to federal approval. This change directly affects Medicaid beneficiaries and healthcare providers through more reliable service delivery.

HB 1461 requires Maryland insurers, nonprofit health plans, and health maintenance organizations to cover specialty drugs for rheumatologic conditions (like rheumatoid arthritis) when administered or dispensed by in-network rheumatology providers meeting state regulations. It prohibits insurers from excluding coverage for these drugs based solely on the provider’s location (e.g., office-based vs. specialty pharmacy) and mandates fair reimbursement rates comparable to those paid to designated specialty pharmacies. The bill specifically applies to oral medications requiring complex dosing, auto-injected drugs, or those used with infusion therapies. It does not override medical necessity standards for coverage denial but aims to prevent treatment delays and ensure access to office-based care for patients with chronic rheumatologic conditions.

HB 1469 requires Maryland’s Insurance Administration to create a workgroup to study the current definition of "specialty drug" in health insurance. The workgroup, including pharmacy benefits managers, pharmacists, insurers, hospitals, and healthcare providers, will examine how the definition impacts patients and stakeholders, compare it to federal and state standards, and recommend a revised definition. It must submit findings and recommendations to the Governor and legislature by January 1, 2027, after which the bill expires on June 30, 2027. This bill directly affects health insurers, pharmacies, hospitals, and patients using high-cost specialty drugs, aiming to clarify definitions that influence coverage and costs.

SB 486 expands Maryland's Graduate and Professional Scholarship Program to include students at the University of Maryland Eastern Shore (UMES) in specific graduate programs. It adds UMES as an eligible institution for students enrolled in four programs: Master of Medical Science in Physician Assistant Studies, Doctor of Pharmacy, Doctor of Physical Therapy, and Doctor of Veterinary Medicine. This change directly affects UMES students in these fields who previously could not access the scholarship. The bill amends existing law to update the list of qualifying institutions without changing scholarship amounts ($1,000-$5,000 per year) or other program rules. The change takes effect July 1, 2026.

HB 88 allows Maryland health insurers, nonprofit health service plans, and health maintenance organizations (HMOs) to join group buying pools for prescription drugs. This enables these entities to collectively purchase medications at potentially lower costs, directly affecting the price of covered drugs for plan members. The bill authorizes participation in such pools for entities providing prescription drug coverage through pharmacy benefit managers. It will take effect October 1, 2026, but does not require participation or guarantee cost savings.